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Role of medical therapy in the
management of uterine adenomyosis
Silvia Vannuccini, M.D.,a Stefano Luisi, M.D., Ph.D.,b Claudia Tosti, M.D.,b Flavia Sorbi, M.D.,c
and Felice Petraglia, M.D.c
a Department of Health Sciences, University of Florence, Obstetrics and Gynecology, Careggi University Hospital, Florence;
b Department of Molecular and Developmental Medicine, University of Siena, Siena; and c Department of Experimental,
Clinical and Biomedical Sciences, University of Florence, Obstetrics and Gynecology, Careggi University Hospital,
Florence, ItalyAdenomyosis is a benign uterine condition affecting women at various ages with different symptoms. The management of these pa-
tients is still controversial. Few clinical studies focusing on medical or surgical treatment for adenomyosis have been performed. No
drug is currently labelled for adenomyosis and there are no specific guidelines to follow for the best management. Anyhow, medical
treatments are effective in improving symptoms (pain, abnormal uterine bleeding and infertility). The rationale for using medical treat-
ment is based on the pathogenetic mechanisms of adenomyosis: sex steroid hormones aberrations, impaired apoptosis, and increased
inflammation. Several nonhormonal (i.e., nonsteroidal anti-inflammatory drugs) and hormonal treatments (i.e., progestins, oral con-
traceptives, gonadotropin-releasing hormone analogues) are currently used off-label to control pain symptoms and abnormal uterine
bleeding in adenomyosis. Gonadotropin-releasing hormone analogues are indicated before fertility treatments to improve the chances
of pregnancy in infertile women with adenomyosis. An antiproliferative and anti-inflammatory effect of progestins, such as dienogest,
danazol and norethindrone acetate, suggests their use inmedical management of adenomyosis mainly to control pain symptoms. On the
other hand, the intrauterine device releasing levonorgestrel resulted is extremely effective in resolving abnormal uterine bleeding and
reducing uterine volume in a long-term management plan. Based on new findings on pathogenetic mechanisms, new drugs are under
development for the treatment of adenomyosis, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid,
and anti-platelets therapy (Fertil Steril 2018;109:398–405. 2018 by American Society for Reproductive Medicine.)
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and-sterility/posts/29154-25442A denomyosis is a uterine disordercharacterized by pelvic painsymptoms, abnormal uterine
bleeding (AUB), and infertility (1). The
clinical presentation is often mixed,
and thanks to the improvement in
imaging diagnostic accuracy (2–4),
adenomyosis may be detected also
in a relatively high proportion of
asymptomatic women (5). Depending
on a woman's age, reproductive status,
and clinical symptoms, adenomyosis may
also require a life-long management
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398infertility treatment may play a role,
alone or in combination (6).
The disease is no longer considered
typical of women over 40 years of
age and around 30% of young women
are affected by adenomyosis (7–9).
Moreover, adenomyosis is diagnosed
in 22% of infertile women less than
40 years old undergoing assisted
reproductive technologies (ART) (10).
Thus, a conservative management
aiming to preserve or restore fertility
and manage clinical symptoms
should be considered. In addition,8; accepted January 9, 2018.
e. C.T. has nothing to disclose. F.S. has nothing to
and Gynecology, Department of Experimental,
lorence, Largo Brambilla 3, Florence 50134, Italy
015-0282/$36.00
Medicine, Published by Elsevier Inc.adenomyosis very often coexists with
other gynecological comorbidities,
such as endometriosis and uterine
fibroids, conditions to be considered
in the management plan (11, 12).
Although few randomized double-
blind clinical studies focusing on med-
ical treatment for adenomyosis have
been performed, nowadays medical
therapy shows increasing efficacy in
patients requiring control of symptoms
or fertility treatments. However, no
drug is currently labelled for adeno-
myosis and there are no specific guide-
lines to follow for the best
management. The intended outcome
of treating symptomatic adenomyosis
is the relief of signs and symptoms,
maintenance or improvement of
fertility, while minimizing side effects.
The rationale for using medical
treatment is based on the pathogenetic
mechanisms of adenomyosis, most of
them shared with endometriosis.VOL. 109 NO. 3 / MARCH 2018
Fertility and Sterility®Adenomyosis in fact is a sex steroid hormone-dependent dis-
order, characterized by increased inflammation, impaired
apoptosis, and neuroangiogenesis (13). Several nonhormonal
(i.e., nonsteroidal anti-inflammatory drugs [NSAIDs]) and
hormonal treatments (i.e., progestins, oral contraceptives,
gonadotropin-releasing hormone [GnRH] analogues) (14)
are currently used off-label to control pain symptoms and
AUB in adenomyosis (15). New insight in adenomyosis path-
ogenesis and new potential therapeutic targets have been
identified through animal and in vitro studies, thus it is hoped
that they will lead to further clinical studies on new com-
pounds and treatment targets in this heterogeneous disease.GnRH ANALOGUES
The rationale for using GnRH analogues for medical treat-
ment of adenomyosis is the direct antiproliferative effect
within the myometrium through the action on the GnRH re-
ceptors expressed by adenomyotic lesions, together with a
systemic and local hypoestrogenic effect through a central
downregulation and a deep suppression of gonadotropin
secretion (16, 17). In fact, adenomyosis is characterized by
an hyperestrogenism due to an increased expression of
estrogen receptors, an activation of sulphatase and
aromatase and a reduced local catabolism of estrogens. This
condition, in turn, contributes to induce a down-regulation
of progesterone receptors, a loss of their action, and finally,
progesterone resistance (13). However, GnRH analogues also
act on other pathogenetic mechanisms, by inducing apoptosis
in adenomyotic tissues, reducing inflammation and angio-
genesis (18). In addition, GnRH analogues are able to mark-
edly reduce the expression of nitric oxide synthases and
peroxynitrite, suppressing the serum levels of nitrite/nitrate,TABLE 1
Summary of commonly used drugs for adenomyosis.
Class of compound Mechanisms of action
























COCs Decidualization and subsequent
atrophy of the endometrium
Benefit
ame
NSAIDs Reduced prostaglandins synthesis Reduce
Note: COCs¼ combined oral contraceptives; GnRH analogues¼ gonadotropin releasing hormone a
inflammatory drugs.
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in adenomyosis (19).
The first reported case of adenomyosis treated using
GnRH analogues showed a significant reduction of uterine
volume, with relief of severe symptoms (20). Goserelin, leu-
prolide and nafarelin are commonly used in clinical practice
(14), causing uterine size reduction and an improvement in
pelvic pain and bleeding (20–22) (Table 1). However, the use
of GnRH analogues is associated with hypoestrogenic side
effects, including vasomotor syndrome, reduced bone
mineral density, genital atrophy, and mood instability.
Therefore, an add-back therapy should be used to minimize
side effects, even if a long-term treatment with GnRH ana-
logues should be restricted to women unresponsive to other
medications or in surgically high-risk patients. However,
there is no specific indication on when and which type of
add-back therapy should be used in case of severe vasomotor
symptoms or to prevent bone loss when GnRH analogues are
prescribed for adenomyosis (23). The option to use long-term,
low-dose GnRH analogues, so-called draw-back therapy, was
tested in a small sample of women with adenomyosis. Buser-
elin acetate per nasal administration for 2 years allowed
maintenance of plasma estradiol levels within the therapeutic
window, suppressing adverse events while maintaining ther-
apeutic effects on adenomyosis (24).PROGESTINS
Norethindrone Acetate
The rationale for using norethindrone acetate (NETA) is based
on the observation that progestins are able to inhibit
estradiol-induced vascular endothelial growth factor and
stromal cell-derived factor 1 in human endometrial stromalEffects Side effects
ant reduction of uterine size,
ding and pain in short term
od
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d pain and bleeding Gastrointestinal side-effects
nalogues; LNG-IUS¼ levonorgestrel-releasing intrauterine system; NSAIDs¼ nonsteroidal anti-
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VIEWS AND REVIEWScells (25), reducing bleeding and pain. In addition, progestins
may act on the progesterone resistance observed in ectopic
and eutopic endometrium, but also in the inner and outer
layers of the myometrium adenomyosis (13) (Table 1).
An effect of NETA in the management of adenomyosis
has been demonstrated in women with moderate or severe
pelvic pain and bleeding, obtaining a significant impro-
vement of both dysmenorrhea and bleeding after treatment
(5 mg/d dose) (26) (Table 1). In this treatment group, the ‘three
weeks on, one week off’ regime was adopted to minimize the
common side effect of breakthrough bleeding, causing an
incomplete suppression of the hypothalamic-pituitary-
ovarian axis and a less hypoestrogenic effect. According to
these results, NETA may be considered an effective, well-
tolerated and inexpensive medical treatment for adenomyo-
sis, with few andmild side effects. However, no further studies
have been conducted comparing NETA to other progestins or
other drug, and no evidences are available on long term ef-
fects on symptoms and sonographic or magnetic resonance
imaging appearance of adenomyosis after discontinuation
of NETA treatment.Danazol
Danazol, an isoxazole derivative of 12 aloha-ethinyl testos-
terone, has strong antigonadotropic properties (27), lowering
the mid-cycle luteinizing hormone surge and increasing serum
free testosterone levels (28). The androgenic and hypoestro-
genic milieu cause both a direct effect on adenomyotic lesions
and an indirect effect on symtoms (29). Studies in vitro showed
danazol has a direct effect on cell proliferation, by inhibiting
DNA synthesis and inducing apoptosis. Glands and stromal
cells of adenomyosis analyzed after systemic treatment with
danazol show a reduction in estrogen receptor and bcl-2 pro-
tein concentrations, with an increase in apoptotic cell necrosis
(30). Danazol also inhibits lymphocyte proliferation, reduces
monocyte-enhanced endometrial proliferation in peripheral
blood and increases peritoneal macrophage cytotoxicity (31,
32). The study by Ota et al. (33), the only randomized
controlled trial on danazol, compared hysterectomy versus a
4 month treatment with 400 mg of daily danazol; post-
treatment autoantibody levels and antiphospholipid levels
were decreased, due to the inhibitory effect of danazol on the
autoimmunological response associated with adenomyosis.
Limited evidence is available on systemic treatment of
adenomyosis with danazol, due to the high incidence of
androgenic side effects. The first to use danazol to treat ad-
enomyosis in a different route than the systemic one was Igar-
ashi who used an intrauterine device containing 175 mg of
danazol. The treatment resulted effective in reducing the
size of the uterus and pregnancy was achieved in 66.6% cases
(34). Cervical injections of danazol at 2 week intervals for
12 weeks have also been successfully used, with 60%
improvement in symptoms of bleeding, pain, and dyspareu-
nia, and a decrease in uterine size (35). Also an intrauterine
device loaded with 300 mg–400 mg of danazol caused a great
reduction of pain symptoms. During the treatment, blood da-
nazol levels were undetectable, ovulation was not inhibited,
and no side effects were reported (36). The same device loaded400with danazol was used in a murine model, and it was observed
that as the danazol dose increased, the adenomyotic nodule
number decreased, with a low and stable plasma danazol con-
centration (37).
A prospective study showed long-term vaginal adminis-
tration of one 200 mg danazol tablet every day is effective
in reducing heavy menstrual bleeding and pain in adenomy-
otic women (38) (Table 1). Recently, it was observed that a
long-term treatment with vaginal danazol can control pain
and AUB in women with adenomyosis. There was an
improvement in visual analogue scale score for pain symp-
toms, pictorial blood-loss assessment chart for uterine
bleeding and quality-of-life measures, with a reduction of
uterine volume evaluated by ultrasound. The 6-month treat-
ment followed by a cyclic 3-month treatment for a further
18 months had the best compliance in symptomatic patients
with adenomyosis (39).
The positive changes induced by danazol were mark-
edly increased compared with leuprolide acetate, although,
even after 6 months of therapy, menorrhagia and dysmen-
orrhea recurred within a few cycles of treatment suspension
of danazol (30).Dienogest
Dienogest (DNG), a 19-nortestosterone derivative, is a proges-
tin with high selectivity for progesterone receptors (40). It
causes a mild inhibition of ovarian function, with slight hy-
poestrogenic effects, and it exerts an antiproliferative action
on the endometrium (41). Cellular proliferation of adenomy-
otic cells is inhibited also by inducing apoptotic pathways
(42). In addition, uterine samples taken after hysterectomy
from women treated with DNG showed significant changes
in histological features, such as reduction in cell proliferation,
nerve growth factor expression and nerve fiber density (21).
These findings support the clinical evidences that DNG is
effective in treating adenomyosis-associated pain symptoms
(Table 1). On the basis of significant changes in the immune
system, with an increased number of uterine infiltrating nat-
ural killer cells in glandular structure of eutopic endometrium,
a potential beneficial effect on embryo implantation has also
been hypothesized (43).
The first pilot study on DNG was conducted in seventeen
premenopausal women with symptomatic adenomyosis and
the drug resulted effective in improving the pain symptoms,
although some of them experienced more frequent menor-
rhagia with worsening of anemia (44). A randomized,
double-blind, multicenter, and placebo-controlled trial on
DNG, daily administered for 16 weeks in women with adeno-
myosis, showed a significant decrease of pain score and visual
analogue scale betweenDNGand placebo (45). A greater reduc-
tion of uterine volume in the DNG groupwas observed, without
reaching significance. The drug was well-tolerated, although a
high portion of women reported irregular uterine bleeding dur-
ing treatment.
Another recent study from the same group evaluated
safety and efficacy of long-term administration of DNG
(52 weeks) (46). DNG resulted effective in reducing pain-
score scale for dysmenorrhea and pelvic pain and inVOL. 109 NO. 3 / MARCH 2018
Fertility and Sterility®decreasing the need for analgesics. Pain score significantly
decreased after 24 and 52 weeks of treatment improving pa-
tients' quality of life. In fact, the Bodily Pain subscale score
in SF-36 was almost the same for the general population.
The most common adverse drug reactions included metror-
rhagia (96.9%) and hot flush (7.7%), but in most cases the
bleeding, due to the progestational action of DNG on the
endometrium, was tolerable. However, a retrospective study
(on 51 patients) showed that young age and anemia prior to
treatment were risk factors for cessation of treatment with
DNG (47).
The comparison between DNG and GnRH analogues
showed no difference in terms of pelvic pain reduction, as
both were effective in pain control. However, four months
of treatment with GnRH analogues induced a greater reduc-
tion of AUB symptoms and uterine volume evaluated by
ultrasound (48).Levonorgestrel-releasing Intrauterine System
Levonorgestrel-releasing intrauterine system (LNG-IUS) has
been successfully used to treat adenomyosis with the aim to
reduce menstrual blood loss and pain via a reduction in thick-
ness of the myometrial junctional zone and total uterine vol-
ume (49–51) (Table 1). LNG-IUS is effective in reducing
menstrual bleeding, even in women without adenomyosis
and is inserted for contraceptive needs (52). The reduction
of menstrual blood loss is attributed to both direct effect of le-
vonorgestrel on adenomyosis foci with decidualization and
increase in apoptosis in endometrial glands and stroma (53).
In fact, local levonorgestrel release caused atrophy and
shrinkage of adenomyotic lesions through a downregulation
of estrogen receptors, preventing further stimulation by estro-
gens (54). The LNG-IUS guarantees reduction in side effects
caused by other oral treatment providing, in contrast with
relatively low serum levels, locally high concentrations of
LNG in the endometrium and adjacent tissues.
LNG-IUS is an effective and simple alternative method for
the treatment of chronic pelvic pain. This is a cost effective,
reversible, and long-term treatment for women with pelvic
pain associated with adenomyosis, especially mild and
moderately severe (55), reducing the need for surgical
interventions.
In women treated with LNG-IUS for 3 years there was an
overall satisfaction of 72%, with continued significant
decrease in dysmenorrhea and uterine volume compared to
baseline (56). Even though pain reduction improves quite
rapidly, uterine volume reduction may not occur until 2 years
post insertion (57). LNG-IUS action towards bleeding is medi-
ated by a reduction in Vascular endothelial growth factor,
endometrial levels (58). A randomized controlled-trial on 75
women undergoing either LNG-IUS or hysterectomy showed
that 6 months post treatment hemoglobin levels were compa-
rable and quality of life increased with LNG-IUS versus hys-
terectomy (59).
LNG-IUS showed effective in reduction of urinary symp-
toms at 6 months post treatment and improvement in incon-
tinence in 65 women with sonographic adenomyosis
prospectively enrolled (60). Zhang et al. (61) performed a pro-VOL. 109 NO. 3 / MARCH 2018spective study on 21 women with a uterine size of<12 weeks
gestation treated with GnRH analogues until uterine size
reduction <10 weeks gestation. Then LNG-IUS was inserted,
and after 12 months of combined treatment, women had
significantly reduced menstrual bleeding and dysmenorrhea,
with a reduced uterine size, and a low LNG-IUS expulsion
rate.
A randomized clinical trial comparing combined oral
contraceptives (COCs) vs LNG-IUS showed both reduced
pain and menstrual loss, but the intrauterine device is more
effective in these outcomes (62). To date, the cutoff value of
uterine volume more than 150 mL was significantly associ-
ated with failure of LNG-IUS, thus the insertion of an LNG-
IUS in a large volume uterus has a significantly higher failure
rate than that of a small volume uterus (63).COMBINED ORAL CONTRACEPTIVES
The rationale for using COCs in adenomyosis is related to the
induced decidualization and subsequent atrophy of the endo-
metrium, reducing pain and AUB (Table 1). Patients with
dysmenorrhea and menorrhagia in fact may benefit from
the resulting amenorrhea, which may provide relief of symp-
toms (64). In addition, COCs suppress aromatase expression in
the eutopic endometrium and in adenomyotic foci (65).
Despite the common off-label use of COCs for adenomyosis-
related symptoms with satisfactory long-term pain control,
no well conducted randomized controlled trials are available
supporting the pharmacological treatment of adenomyosis
using COCs.NON-STEROIDAL ANTI-INFLAMMATORY
DRUGS
Non-steroidal anti-inflammatory drugs (NSAIDs) are non-
hormonal compounds commonly used as a symptomatic
treatment for dysmenorrhea and heavy bleeding associated
with adenomyosis (Table 1). A systematic review showed
that they are effective in treating menstrual pain, without
indicating which drug is the most appropriate and the safest
for this purpose (66). Another systematic review reported
that NSAIDs may be used for reducing menstrual bleeding,
even though they are less effective than hormonal treatment
or tranexamic acid (67). However, no specific studies on the
use of NSAIDs in adenomyosis are currently available.NOVEL DRUGS UNDER INVESTIGATION
Aromatase Inhibitors
Aromatase cytochrome P450 (CYP19A1), a key enzyme in the
synthesis of estrogen from androgens, is typically found in
the endometrium of women with endometriosis, adenomyosis
and leiomyomas, but not in that of healthy women (68, 69).
This enzyme is involved in the conversion of
androstenedione and testosterone to estrone and estradiol,
respectively. The first documented use of aromatase
inhibitors (AIs) in adenomyosis was reported in a woman
with severe adenomyosis refractory to GnRH analogues and
danazol, who wished to preserve her fertility. Anastrozole
was administered orally for 16 weeks, in combination with401
VIEWS AND REVIEWSGnRH analogues, to suppress the ovarian production of
estrogens. Reduction of uterine volume was 60% after
8 weeks of treatment and the patient had no AUB for
6 months after cessation of AI administration (70). Results
from a randomized controlled-trial comparing a treatment
for 3 months with an aromatase inhibitor (letrozole 2.5 mg/d)
and goserelin 3.6 mg monthly showed that AIs have the
same efficacy as GnRH analogues in reducing adenomyoma
volume and improving symptoms. In fact in both treatments
a significant difference in uterine volume after 3 months was
observed, without a relevant change in adenomyotic area
(41% vs. 49%) at study completion (71). AIs seems to have a
promising future for adenomyosis in cases of resistance to
other treatments even though additional studies are needed (6).Selective Progesterone Receptor Modulators
The progesterone receptors play an essential role in uterine
physiology and reproduction. Selective progesterone receptor
modulators (SPRMs) have emerged as a valuable treatment
option for hormone dependent conditions like uterine fibroids
(72). SPRMs exhibit progesterone agonist and antagonist ac-
tivities in the endometrium, reducing pain, bleeding, cell pro-
liferation and inhibiting inflammation (73, 74), thus they may
be a promising treatment for endometriosis and adenomyosis
as well. Previous evidences on mifepristone showed that it
influences the caspase 3 expression in adenomyosis tissue,
inducing cell apoptosis, inhibiting the onset and
development of adenomyosis (75). However, only a few
small clinical studies on endometriosis showed the potential
application of SPRMs in adenomyosis. The administration
of mifepristone 50-mg daily improved pain and caused
regression of endometriotic lesions (76). Similarly, asoprisnil
and telapristone acetate have also been reported to relieve
endometriosis-associated pain (77). However, SPRMs require
investigations and well designed, randomized controlled tri-
als to assess their long-term effects and their clinical use in
patients with adenomyosis. A phase II, randomized, double-
blind, controlled trial with ulipristal acetate 10 mg/day for
3 months in patients with adenomyosis wishing to keep
fertility has just been registered. The primary outcome is to
evaluate the efficiency of ulipristal acetate on bleeding con-
trol and pain in adenomyosis.GnRH Antagonists
GnRH-antagonists (GnRH-ant) are peptide compounds with a
structure similar to natural GnRH that inhibit the reproductive
system through an immediate antagonist action on GnRH re-
ceptors in the pituitary, blocking the secretion of gonadotro-
pins. They are usually used in antagonist stimulation
protocols in ART. Recently, two double-blind, randomized,
phase 3 trials on women with endometriosis treated with
different doses of elagolix, an oral nonpeptide GnRH-ant,
were published (78). Both schedules of elagolix were effective
in improving dysmenorrhea and nonmenstrual pelvic pain
during a 6-month period in women with moderate to severe
endometriosis-associated pain (78) The mechanism of action
of GnRH-ant is different from that of GnRH analogues which402after an initial stimulatory phase desensitize GnRH receptors
in the pituitary and subsequently cause depletion of pituitary
gonadotropins and full suppression of estradiol. GnRH-ant do
not induce neither downregulation nor desensitization of the
receptors, as they act competitively preventing endogenous
GnRH from binding and activating its pituitary receptor.
Thus, depending on the dose of antagonist administered, the
estradiol suppression can be modulated. The treatment may
partially suppress estradiol without having to administer add-
back therapy, or fully suppress estradiol when combined with
add-back therapy (79). Considering the promising results of
GnRH-ant in endometriosis, a future use for treating
adenomyosis-related symptoms may be hypothesized.Valproic Acid
Increasing evidence is showing that adenomyosis is an epige-
netic disease (13). Class I histone deacetylases seem to be
involved in the pathogenesis, as their expression has been
found to be increased in eutopic and ectopic endometrium in
adenomyosis, correlating with severity of dysmenorrhea
(80). Valproic acid (VPA), a specific and potent histone deace-
tylase inhibitor, used for decades for treating epilepsy, has
been shown to be effective in treating a small series of women
with adenomyosis, decreasing dysmenorrhea and uterine
bleeding, and reducing the uterus size (81, 82). Studies on
murine models of adenomyosis showed the mechanism of
action of VPA, that suppressed myometrial infiltration,
improved generalized hyperalgesia, and reduced the
amplitude and irregularity of uterine contractions (83, 84).
Despite these promising results in favor of the use of histone
deacetylase inhibitors, so far no clinical trials have been
conducted to evaluate the efficacy of VPA in adenomyosis.Anti-platelet Therapy
Emerging evidence supports an important role of platelets in
adenomyosis pathogenesis, according to the theory that ad-
enomyotic lesions are wounds undergoing repeated tissue
injury and repair (85). Platelets induce epithelial-
mesenchymal transition, fibroblast-to-myofibroblast trans-
differentiation, leading ultimately to fibrosis (86). A recent
study in a mouse model of adenomyosis demonstrated that
anti-platelet treatment (thromboxane A2 synthese inhibitor)
is efficacious in suppressing myometrial infiltration,
improving generalized hyperalgesia, reducing both uterine
hyperactivity and systemic corticosterone levels. In addition,
a decreased expression of some proteins involved in adeno-
myosis fibrogenesis was demonstrated, supporting the prom-
ising role of anti-platelets therapy in adenomyosis (87).
However, so far there are currently no studies published or
registered on the use of agents targeting platelets.
MEDICAL TREATMENT IN INFERTILE WOMEN
WITH ADENOMYOSIS
The presence of adenomyosis is diagnosed in a higher fre-
quency in patients consulting with fertility problems, with a
prevalence ranging from 20%–25% in women undergoing
ART (10). A dysregulation of the myometrial structure andVOL. 109 NO. 3 / MARCH 2018
Fertility and Sterility®an altered endometrial function contributes to the negative
impact of adenomyosis on fertility (88, 89). However, there
is no agreement on the most appropriate therapeutic
methods for managing women with adenomyosis trying to
conceive. A number of studies have shown that GnRH
treatment may improve the reproductive performance,
possibly promoting uterine and endometrial receptivity (90).
The first case reports on the use of GnRH analogues showed
that after a 6-month treatment with nafarelin acetate or a
5-month treatment with leuprolide acetate respectively, two
women with severe adenomyosis spontaneously conceived
(91, 92). The use of GnRH analogues was tested also both
before and after surgical treatment for adenomyosis, with
relatively good results for fertility, even though only small
series or case reports supported this management (90, 93,
94). Some studies have shown that administration of GnRH
analogues before in vitro fertilization (IVF) cycles
significantly increases the chances of pregnancy in infertile
women with adenomyosis or endometriosis (95–97). Niu
et al. (98) demonstrated that long-term GnRH agonist pre-
treatment improves pregnancy outcomes in adenomyosis pa-
tients undergoing frozen embryo transfer (FET) after
preparation of the endometrium with hormone replacement
therapy (98). Another recent retrospective study was conduct-
ed on 241 infertile women with adenomyosis diagnosed by
ultrasound undergoing IVF and fresh embryo transfer (ET) cy-
cles or FET cycles. Results showed no difference between
cases with or without GnRH analogues pretreatment with go-
serelin for 2-3 months in a large number of fresh ET cycles,
indicating that GnRH analogues pretreatment has no benefit
in improving IVF outcomes in these cases. On the contrary, a
higher clinical pregnancy rate was observed in women under-
going FET cycles after GnRH pretreatment (39.5%) than those
undergoing to fresh ET with (30.5%) or without (25.2%) GnRH
analogues pretreatment (99).
A very recent systematic review andmeta-analysis summa-
rized the existing evidence related to the effect of adenomyosis
on fertility and on IVF clinical outcomes, showing that pretreat-
ment with the use of long-term GnRH analogues or long proto-
col could be beneficial in increasing the clinical pregnancy rate,
both in symptomatic and asymptomatic patients (100). Adeno-
myosis has a detrimental effect on IVF clinical outcomes,
reducing pregnancy and live birth rates and increases the
miscarriage rate. Pre-IVF treatment with the use of GnRH ana-
logues down-regulation may be beneficial, but further studies
are needed (100).CONCLUSIONS
Medical treatment plays an important role in themanagement
of adenomyosis, especially in diffuse forms and in those
women requiring preservation or restoration of fertility. Med-
ical management is a valid choice for treating pain symptoms
and bleeding, resulting very frequently in a more acceptable
option than surgical treatment. So far, no labelled drugs are
available, however those commonly used are effective in
managing symptoms and improving pregnancy rate in ART.
Randomized clinical studies are needed to systematically
test the clinical usefulness of drugs commonly used and iden-VOL. 109 NO. 3 / MARCH 2018tify the most effective ones. In addition, on the basis of the
new discoveries on pathogenetic mechanisms of adenomyo-
sis, the introduction of new molecules is desirable.REFERENCES
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